KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Construction in Progress: 2023-2025

Historic Construction in Progress for AbCellera Biologics (ABCL) over the last 3 years, with Sep 2025 value amounting to $118.7 million.

  • AbCellera Biologics' Construction in Progress rose 27.63% to $118.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.7 million, marking a year-over-year increase of 27.63%. This contributed to the annual value of $103.2 million for FY2024, which is 13.41% up from last year.
  • As of Q3 2025, AbCellera Biologics' Construction in Progress stood at $118.7 million, which was up 2.33% from $116.0 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Construction in Progress ranged from a high of $118.7 million in Q3 2025 and a low of $10.5 million during Q2 2023.
  • In the last 3 years, AbCellera Biologics' Construction in Progress had a median value of $92.0 million in 2023 and averaged $68.2 million.
  • Data for AbCellera Biologics' Construction in Progress shows a peak YoY surged of 792.31% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows AbCellera Biologics' Construction in Progress stood at $91.0 million in 2023, then rose by 13.41% to $103.2 million in 2024, then rose by 27.63% to $118.7 million in 2025.
  • Its Construction in Progress stands at $118.7 million for Q3 2025, versus $116.0 million for Q2 2025 and $108.6 million for Q1 2025.